一项测试鼓室内注射地塞米松治疗严重致残性耳鸣有效性的研究
A Study to Test the Effectiveness of Intratympanic Dexamethasone Injections as a Treatment for Severe Disabling Tinnitus.
文献信息
| PMID | 42732646 |
|---|---|
| 原文 | 在 PubMed 查看原文 ↗ |
| 发表日期 | 2026 |
| 作者 | Asma Mohd Shoukat |
| 作者单位 | Department of Otorhinolaryngology and Head & Neck Surgery, MNR Medical College, Patancheru, Hyderabad, India. |
| 期刊 | The journal of international advanced otology |
| SCI 分区 | Q3 |
| IF | 1.3 |
| 研究类型 | 临床研究 · 临床 |
| 所属专科 | 耳科 |
中文摘要
背景： 耳鸣是在没有外部声源的情况下感知到声音，常与听力损伤相关。主观性耳鸣影响约10%的人口，在许多病例中未发现明确病因，被归类为特发性。鼓室内皮质类固醇因其靶向治疗作用而受到关注。本研究探讨鼓室内地塞米松在治疗特发性耳蜗性耳鸣中的作用。本研究的目的是评估鼓室内注射地塞米松在伴有或不伴有感音神经性听力损失的严重致残性耳鸣患者中的有效性。
方法： 一项描述性观察研究于2019年10月至2021年9月在Navodaya医学院及医院耳鼻咽喉科进行。纳入65例年龄18-60岁、耳鸣持续时间至少1个月并伴有感音神经性听力损失的患者。使用耳鸣残疾量表（THI）评估耳鸣严重程度。患者每周接受鼓室内地塞米松（4 mg/mL，0.4-0.6 mL）注射，持续4周，并在治疗结束时评估结果。
结果： 大多数患者为男性（60%）且年龄低于30岁。治疗后观察到THI评分显著改善，轻度病例从21.5%增加至67.7%，中度病例从63.1%下降至32.3%，重度病例从15.4%降至0%（P < .05）。并发症极少。
结论： 鼓室内地塞米松与特发性耳鸣患者耳鸣严重程度降低相关，无论是否伴有感音神经性听力损失。由于这是一项无对照组的单臂研究，这些发现需谨慎解读，尚待随机对照试验验证。
英文摘要
BACKGROUND: Tinnitus is the perception of sound without an external source and is frequently linked with hearing impairment. Subjective tin-nitus affects approximately 10% of the population, and in many cases, no cause is identified, classified as idiopathic. Intratympanic corticosteroids have gained attention for their targeted therapeutic effects. This study explores intratympanic dexamethasone in managing idiopathic cochlear tinnitus. Objective of this study is to evaluate the effectiveness of intratympanic dexamethasone injections in patients with severe disabling tin-nitus associated with or without sensorineural hearing loss.
METHODS: A descriptive observational study was conducted in the Department of Otorhinolaryngology at Navodaya Medical College and Hospital from October 2019 to September 2021. Sixty-five patients aged 18-60 years with tinnitus of at least 1-month duration and associated sensorineural hearing loss were included. Tinnitus severity was assessed using the Tinnitus Handicap Inventory (THI). Patients received intratympanic dexamethasone (4 mg/mL, 0.4-0.6 mL) weekly for 4 weeks, with outcomes evaluated at completion.
RESULTS: The majority of patients were male (60%) and below 30 years of age. Significant improvement in THI scores was observed post-treatment, with mild cases increasing from 21.5% to 67.7%, moderate cases decreasing from 63.1% to 32.3%, and severe cases reducing from 15.4% to 0% (P < .05). Minimal complications were noted.
CONCLUSION: Intratympanic dexamethasone was associated with reduced tinnitus severity in patients with idiopathic tinnitus, with or without sensorineural hearing loss. As this was a single-arm study without a control group, these findings warrant cautious interpretation pending validation in randomized controlled trials.